Legal Challenge to CMS Hemp Strategy Raises Concerns Over FDA Authority
A federal lawsuit in the U.S. District Court for the District of Columbia is challenging the legality of the Centers for Medicare & Medicaid Services' (CMS) Beneficiary Engagement Incentive (BEI) model. This program allows the furnishing of certain hemp-derived cannabinoid products to Medicare beneficiaries without U.S. Food and Drug Administration (FDA) approval. The case, Smart Approaches to Marijuana (SAM) et al. v. Robert F. Kennedy Jr. et al., questions whether CMS can introduce cannabinoid products into Medicare-connected environments without the traditional FDA approval process. Critics argue that this policy shift undermines the established sequence of science, clinical trials, FDA approval, and coverage integration, potentially signaling that clinical evidence is optional. 
